Taxi cab drivers aid dementia research in brain trial

black cab

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

UCL aims to help drive the fight against dementia by enlisting London’s Black Cab drivers in a unique brain testing trial.

London’s black cab drivers, famed for their ability to plan routes by remembering thousands of the capital’s streets, are playing a vital role in advancing dementia research. The Taxi Brains Project, run by The Spatial Cognition Group at University College London, is analysing taxi drivers’ brains via MRI scans as they plan routes through London.

Longevity.Technology: Possessing a larger part of the brain that shrinks early in Alzheimer’s disease – the hippocampus – licensed black cab drivers are a unique test group and the results of the trial will help provide critical insights in helping science to develop diagnostics to detect Alzheimer’s disease earlier.

Alzheimer’s disease is by far the most prevalent degenerative dementia, and there are nearly 10 million new cases every year [1]; the disease is an enormous burden globally, both for patients, families and healthcare systems, and there is no known cure. Understanding more about the way the disease takes hold and being able to identify it earlier will lead to better outcomes for sufferers as well as progress towards improving therapy.

By completing the Knowledge of London, acquired through years of training in specific Knowledge Schools, London’s cabbies learn to navigate through the city’s 58,000 streets without the use of GPS and automated instructions.

As well as always having had a famous person in the back of their cab once, London’s taxi drivers have another remarkable feature – their brains have larger hippocampi [2].

The hippocampus is essential for forming new memories, such as who was on the ‘phone or what you needed to add to your shopping order. However, Alzheimer’s patients suffer progressive shrinkage of the hippocampus, and this is responsible for the short-term memory loss that is one of the hallmark symptom of Alzheimer’s disease.

LEVC
London taxi cab driver Peter Powell of LEVC has already taken part in the brain test

“Understanding which parts of the hippocampus get bigger in relation to navigation ability will provide critical insights needed to help develop diagnostics for the earlier detection of Alzheimer’s disease,” explains the Taxi Brains Project. “Early diagnosis will help doctors treat patients sooner, limiting the disease and improving quality of life [3].”

Taxi drivers plan a variety of different routes on the fly on a daily basis; they also have to adapt to changing circumstances such as weather, roadworks and capricious customers. This planning from memory and being able to retain such a vast amount of details has an incredible impact on taxi drivers’ brains. A study discovered that the hippocampus, which is also involved in spatial navigation, is larger in taxi drivers that non taxi drivers [2].

Additionally, research has demonstrated that the hippocampus seems to be part of the brain affected in Alzheimer’s sufferers; this might explain why a symptom of the disease is disorientation and an inability to find their way, sometimes even becoming lost just metres from home. These symptoms often increase in severity as the disease progresses [4].

[1] https://www.who.int/news-room/fact-sheets/detail/dementia
[2] https://www.pnas.org/content/97/8/4398
[3] https://spierslab.com/taxi-brains-project/
[4] https://pubmed.ncbi.nlm.nih.gov/25913063/

Image credits: Yelena Odintsova / Pexels and LEVC

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

This field is hidden when viewing the form
Celularity lands $300m MuseCell manufacturing deal

The latest longevity science, investment, innovation and insight, delivered every morning.

This field is hidden when viewing the form